Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Under-the-Tongue pill aims to help men last longer

NCT ID NCT07434271

Recruiting now Symptom relief Sponsor: Kadence Bio Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called KH-001, taken as a fast-dissolving tablet under the tongue 15 minutes before sex, to see if it helps men with lifelong premature ejaculation last longer. About 40 men in stable relationships will try the drug or a placebo for 4 weeks each, with a break in between. The main goal is to measure changes in how long they can delay ejaculation using a stopwatch held by their partner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KH-001 (a besylate drug in a fast-dissolving tablet taken under the tongue before sex)
What this could lead to
If it works, this could offer a new on-demand treatment to help men with lifelong premature ejaculation last longer during intercourse.
What could go wrong
This is an early Phase 2 study with only 40 men, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREMATURE EJACULATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

premature ejaculation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREMATURE EJACULATION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emeritus Research Sydney

    RECRUITING

    Botany, New South Wales, 2019, Australia

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.